Brought to you by 
Advent and Avista buy Kremers Urban from UCB for $1.5bn, acquisition terminated
29 Sep 2020
Executive Summary
Private equity firms Advent International and Avista Partners paid $1.525bn cash to acquire Kremers Urban Pharmaceuticals Inc., the specialty generics division of UCB Group.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Drug Delivery
- Controlled Release
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advent and Avista buy Kremers Urban from UCB for $1.5bn, acquisition terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice